Bentazepam

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 15:19, 2 April 2016 (Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Bentazepam
Clinical data
Trade namesTiadipona (ES)
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral (tablets)
Legal status
Legal status
Pharmacokinetic data
MetabolismHepatic
Elimination half-life2–4 hours
ExcretionRenal
Identifiers
  • 5-phenyl-3,4,6,7,8,9-hexahydro-[1]benzothiolo[2,3-e][1,4]diazepin-2-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.123.659 Edit this at Wikidata
Chemical and physical data
FormulaC17H16N2OS
Molar mass296.387 g/mol g·mol−1
3D model (JSmol)
  • O=C1CN=C(C2=CC=CC=C2)C3=C(N1)SC4=C3CCCC4
  • InChI=1S/C17H16N2OS/c20-14-10-18-16(11-6-2-1-3-7-11)15-12-8-4-5-9-13(12)21-17(15)19-14/h1-3,6-7H,4-5,8-10H2,(H,19,20) checkY
  • Key:AIZFEOPQVZBNGH-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Bentazepam[1] (also known as Thiadipone, Tiadipona) is a thienodiazepine which is a benzodiazepine analog.[2] It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Peak plasma rates are achieved in around 2,5 hours after oral administration.[3] The elimination half-life is between approximately 2–4 hours.[2][4] Bentazepam is effective as an anxiolytic. A severe benzodiazepine overdose with bentazepam may result in coma and respiratory failure.[5] Adverse effects include dry mouth, somnolence, asthenia, dyspepsia, constipation, nausea[6] and drug-induced lymphocytic colitis has been associated with bentazepam.[7][8] Severe liver damage and hepatitis has also been associated with bentazepam.[9][10][11] Whilst liver failure from bentazepam is considered to be rare, liver function monitoring has been recommended for all patients taking bentazepam.[12]

See also

References

  1. ^ DE Patent 2005276
  2. ^ a b Gonzalez López, F; Mariño, EL; Dominguez-Gil, A (1986). "Pharmacokinetics of tiadipone: a new anxiolytic". International journal of clinical pharmacology, therapy, and toxicology. 24 (9): 482–4. PMID 2877954.
  3. ^ Mariño, EL; Fernandez Lastra, C; Gonzalez Lopez, F; Dominguez-Gil, A; Garcia Santalla, JL; Vorca, G; Izquierdo, JA; Ledesma-Jimeno, A (1987). "Parametrization by non-linear regression and bayesian estimation of bentazepam in a multiple dosage regimen in humans". International journal of clinical pharmacology, therapy, and toxicology. 25 (11): 627–32. PMID 3429066.
  4. ^ Colino, CI; Lastra, CF; López, FG; Ledesma, A; Mariño, EL (1991). "Open-loop feedback control of serum bentazepam concentrations and Bayesian estimation in multiple dosage regimens in patients". International journal of clinical pharmacology, therapy, and toxicology. 29 (11): 457–62. PMID 1800395.
  5. ^ Rivas López, FA; López Soriano, F; Mendoza Cerezo, A; Jiménez Ferré, J; Azurmendi Rodríguez, JI; De La Rubia Nieto (1989). "Mixed benzodiazepine poisoning and reversal with flumazenil (Ro 15-1788)". Revista espanola de anestesiologia y reanimacion. 36 (1): 48–50. PMID 2565591.
  6. ^ Honorato, J; Rubio, A; Tristán, C; Otero, FJ; Garrido, J (1990). "A pharmacovigilance study with bentazepam in a sample of 1046 psychiatric outpatients". Revista de medicina de la Universidad de Navarra. 34 (2): 80–8. PMID 1983365.
  7. ^ Fernández-Bañares, F; Salas, A; Esteve, M; Espinós, J; Forné, M; Viver, JM (2003). "Collagenous and lymphocytic colitis. evaluation of clinical and histological features, response to treatment, and long-term follow-up". The American journal of gastroenterology. 98 (2): 340–7. doi:10.1111/j.1572-0241.2003.07225.x. PMID 12591052.
  8. ^ De-La-Serna, C; Gil-Grande, LA; Sanromán, AL; Gonzalez, M; Ruiz-Del-Arbol, L; Garcia Plaza, A (1997). "Bentazepam-induced hepatic bridging necrosis". Journal of Clinical Gastroenterology. 25 (4): 710–1. doi:10.1097/00004836-199712000-00042. PMID 9451703.
  9. ^ Andrade, RJ; Lucena, MI; Kaplowitz, N; García-Muņoz, B; Borraz, Y; Pachkoria, K; García-Cortés, M; Fernández, MC; et al. (2006). "Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry". Hepatology (Baltimore, Md.). 44 (6): 1581–8. doi:10.1002/hep.21424. PMID 17133470.
  10. ^ Tuca, Albert (2003). "Utilidad clinica del acetato de megestrol para la ganancia de peso en los enfermos con neoplasia y caquexia". Medicina Clinica (in Spanish). 120 (17): 678. doi:10.1157/13047309.
  11. ^ Andrade, RJ; Lucena, MI; Alcantara, R; Fraile, JM (1994). "Bentazepam-associated chronic liver disease". Lancet. 343 (8901): 860. doi:10.1016/S0140-6736(94)92065-6. PMID 7908109.
  12. ^ Andrade, RJ; Lucena, MI; Aguilar, J; Lazo, MD; Camargo, R; Moreno, P; García-Escaño, MD; Marquez, A; et al. (2000). "Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity". Digestive diseases and sciences. 45 (7): 1400–4. doi:10.1023/A:1005520523502. PMID 10961721.